ETON Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (ETON) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $3.8M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| MAIER PAUL V 6 fills | Director | Sell | 100,000 | $59.07 | $5.9M | 73,358 −57.7% of holding | |
| Krempa David | Chief Business Officer | Sell | 25,000 | $65.07 | $1.6M | 37,025 −40.3% of holding | |
| BRYNJELSEN SEAN 3 fills | President & CEO | Sell | 91,022 | $60.70 | $5.5M | 1,004,909 −8.3% of holding | |
| BRYNJELSEN SEAN | President & CEO | Sell | 8,978 | $62.65 | $562.5K | 1,052,216 −0.8% of holding | |
| Opaleye Management Inc. 4 fills | 10% Owner | Sell | 56,630 | $37.54 | $2.1M | 2,665,000 −2.1% of holding | |
| Opaleye Management Inc. 2 fills | 10% Owner | Sell | 26,685 | $38.37 | $1.0M | 2,680,000 −1% of holding | |
| Opaleye Management Inc. | 10% Owner | Sell | 10,000 | $38.00 | $380.0K | 2,700,000 −0.4% of holding | |
| Opaleye Management Inc. 2 fills | 10% Owner | Sell | 90,000 | $37.39 | $3.4M | 2,710,000 −3.2% of holding | |
| Adams Jennifer McKie | Director | Sell | 50,000 | $32.48 | $1.6M | None left | |
| BRYNJELSEN SEAN 2 fills | President & CEO | Sell | 120,000 | $31.88 | $3.8M | 833,842 −12.6% of holding | |
| Krempa David | Chief Business Officer | Sell | 19,679 | $31.47 | $619.4K | 25,249 −43.8% of holding | |
| Krempa David | Chief Business Officer | Sell | 37,524 | $31.49 | $1.2M | 25,249 −59.8% of holding | |
| Krempa David 3 fills | Chief Business Officer | Sell | 42,797 | $33.39 | $1.4M | 35,083 −55% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.